Derazantinib; QAB-087

Lub npe tshuaj:

(6R)-6-(2-fluorophenyl)-5,6-dihydro-N-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-Benzo[h]quinazolin-2-amine

SMILES Code:

COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1

InChi Code:

InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24- 10-4-5-12-2 7(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H ,32,33,34)/t26-/m1/s1

InChi Key:

KPJDVVCDVBFRMU-AREMUKBSSA-N

Lo lus tseem ceeb:

Derazantinib, ARQ-087, ARQ087, ARQ 087, 1234356-69-4

Solubility:Soluble hauv DMSO

Cia:0 - 4 ° C rau lub sijhawm luv (hnub mus rau lub lis piam), lossis -20 ° C rau lub sijhawm ntev (hli).

Nqe lus piav qhia:

Derazantinib, tseem hu ua ARQ-087, yog ib qho kev hais lus bioavailable inhibitor ntawm fibroblast kev loj hlob zoo tshaj plaws receptor (FGFR) uas muaj peev xwm ua haujlwm antineoplastic. FGFR inhibitor ARQ 087 khi rau thiab muaj zog tiv thaiv kev ua haujlwm ntawm FGFR subtypes 1, 2 thiab 3. Qhov no yuav ua rau muaj kev cuam tshuam ntawm FGFR-mediated signal transduction pathways, qog cell proliferation, qog angiogenesis thiab qog cell tuag hauv FGFR-overexpressing qog hlwb. . FGFR, ib qho receptor tyrosine kinase, yog upregulated nyob rau hauv ntau hom qog cell thiab plays lub luag hauj lwm tseem ceeb hauv qog cellular proliferation, sib txawv, angiogenesis thiab ciaj sia taus.

Hom phiaj: FGFR